US2013217677A1PendingUtilityA1
5ht2c receptor modulator compositions and methods of use
Est. expiryDec 23, 2024(expired)· nominal 20-yr term from priority
A61P 9/12A61P 9/10A61P 43/00A61P 3/10A61P 3/06A61P 3/04A61P 3/00A61K 31/135A61K 31/55A61K 31/137
55
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention relates to a composition comprising phentermine and a selective 5HT-2C receptor agonist. In addition, the invention relates to a composition comprising phentermine and a selective 5HT-2C receptor agonist having Formula (I): or a pharmaceutically acceptable salt, solvate or hydrate thereof. These compositions are useful in pharmaceutical compositions whose use includes the treatment of obesity.
Claims
exact text as granted — not AI-modified1 .- 41 . (canceled)
42 . A method of decreasing food intake in a mammal comprising the step of:
administering to said mammal 1,1-dimethyl-2-phenyl-ethylamine, or a pharmaceutically acceptable salt thereof, and (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt thereof.
43 . The method of claim 42 , wherein each of the 1,1-dimethyl-2-phenyl-ethylamine, or a pharmaceutically acceptable salt thereof, and the (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt thereof is formulated for oral administration.
44 . The method of claim 42 , wherein each of the 1,1-dimethyl-2-phenyl-ethylamine, or a pharmaceutically acceptable salt thereof, and the (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt thereof is formulated as a solid dosage form.
45 . The method of claim 42 , wherein each of the 1,1-dimethyl-2-phenyl-ethylamine, or a pharmaceutically acceptable salt thereof, and the (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt thereof is formulated as a liquid dosage form.
46 . The method of claim 42 , wherein the 1,1-dimethyl-2-phenyl-ethylamine, or a pharmaceutically acceptable salt thereof, and the (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt thereof are present in a combined preparation for simultaneous, separate or sequential use.
47 . A method of decreasing food intake in a mammal comprising the step of:
administering to said mammal 1,1-dimethyl-2-phenyl-ethylamine, or a pharmaceutically acceptable salt thereof, and a hydrochloric acid salt of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine.
48 . The method of claim 47 , wherein each of the 1,1-dimethyl-2-phenyl-ethylamine, or a pharmaceutically acceptable salt thereof, and the hydrochloric acid salt of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine is formulated for oral administration.
49 . The method of claim 47 , wherein each of the 1,1-dimethyl-2-phenyl-ethylamine, or a pharmaceutically acceptable salt thereof, and the hydrochloric acid salt of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine is formulated as a solid dosage form.
50 . The method of claim 47 , wherein each of the 1,1-dimethyl-2-phenyl-ethylamine, or a pharmaceutically acceptable salt thereof, and the hydrochloric acid salt of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine is formulated as a liquid dosage form.
51 . The method of claim 47 , wherein the 1,1-dimethyl-2-phenyl-ethylamine, or a pharmaceutically acceptable salt thereof, and the hydrochloric acid salt of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine are present in a combined preparation for simultaneous, separate or sequential use.
52 . A method for preparing a composition comprising 1,1-dimethyl-2-phenyl-ethylamine, or a pharmaceutically acceptable salt thereof, and (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt thereof, said method comprising combining 1,1-dimethyl-2-phenyl-ethylamine, or a pharmaceutically acceptable salt thereof, and (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt thereof.
53 . A method for preparing a composition comprising 1,1-dimethyl-2-phenyl-ethylamine, or a pharmaceutically acceptable salt thereof, and (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt thereof, said method comprising combining 1,1-dimethyl-2-phenyl-ethylamine, or a pharmaceutically acceptable salt thereof, (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers.
54 . A method for preparing a composition comprising 1,1-dimethyl-2-phenyl-ethylamine, or a pharmaceutically acceptable salt thereof, and (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt thereof, said method comprising combining 1,1-dimethyl-2-phenyl-ethylamine, or a pharmaceutically acceptable salt thereof, and (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt thereof to form a tablet or capsule.
55 . A method of preparing a composition comprising 1,1-dimethyl-2-phenyl-ethylamine, or a pharmaceutically acceptable salt thereof, and (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt thereof, said method comprising uniformly mixing 1,1-dimethyl-2-phenyl-ethylamine, or a pharmaceutically acceptable salt thereof, and (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt thereof with one or more liquid excipients and/or solid excipients.
56 . A method of preparing a composition comprising 1,1-dimethyl-2-phenyl-ethylamine, or a pharmaceutically acceptable salt thereof, and (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt thereof, comprising uniformly mixing compound 1,1-dimethyl-2-phenyl-ethylamine, or a pharmaceutically acceptable salt thereof, and (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt thereof with a liquid or a finely divided solid carrier, or both.Join the waitlist — get patent alerts
Track US2013217677A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.